Elizabeth A. Olek
Direttore Tecnico/Scientifico/R&S presso KRONOS BIO, INC.
Patrimonio netto: 189 410 $ in data 30/04/2024
Profilo
Elizabeth A.
Olek is currently working as the Senior Vice President-Clinical Development at Kronos Bio, Inc. She previously worked as the Director-Clinical Research at Genetics Institute LLC from 1998 to 2002, Director-Clinical Research at InterMune, Inc. from 2003 to 2004, Global Brand Medical Director at Novartis Pharmaceuticals Corp.
from 2005 to 2007, Director-Clinical Research at Wyeth Research from 1998 to 2002, Executive Director-Clinical Research at Loxo Oncology, Inc. from 2019 to 2022, and Chief Medical Officer & SVP-Clinical Development at Achillion Pharmaceuticals, Inc. from 2011 to 2012.
Dr. Olek holds a graduate degree from Boston University, an undergraduate degree from the University of the Sciences in Philadelphia, and a doctorate degree from the Philadelphia College of Osteopathic Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
KRONOS BIO INC
0.32% | 21/02/2024 | 193 275 ( 0.32% ) | 189 410 $ | 30/04/2024 |
Posizioni attive di Elizabeth A. Olek
| Società | Posizione | Inizio |
|---|---|---|
| KRONOS BIO, INC. | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Elizabeth A. Olek
| Società | Posizione | Fine |
|---|---|---|
| LOXO ONCOLOGY INC | Corporate Officer/Principal | 01/02/2022 |
| ACHILLION PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 18/06/2012 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/11/2007 |
| INTERMUNE INC | Direttore Tecnico/Scientifico/R&S | 01/07/2004 |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/12/2002 |
Formazione di Elizabeth A. Olek
| Boston University | Graduate Degree |
| University of the Sciences in Philadelphia | Undergraduate Degree |
| Philadelphia College of Osteopathic Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| KRONOS BIO, INC. | Health Technology |
| Aziende private | 6 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Wyeth Research
 Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The private company is based in Cambridge, MA. | Commercial Services |
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
- Borsa valori
- Insiders
- Elizabeth A. Olek
